Efeitos adversos graves no trato gastrointestinal associados aos agonistas de GLP-1 disponíveis no Brasil: uma revisão da literatura
DOI:
https://doi.org/10.11606/issn.1679-9836.v104i2e-227746Palavras-chave:
Efeitos adversos, Agonistas do Receptor de Peptídeo-1 Semelhante a Glucagon, Trato biliar, Trato gastrointestinalResumo
O presente trabalho propõe uma visão geral acerca dos efeitos adversos graves relacionados aos agonistas do receptor de GLP-1 disponíveis no Brasil. Para tanto, foi feita uma revisão da literatura no idioma inglês, através do banco de dados Pubmed, reunindo o corpo de evidências mais atual sobre a associação entre os agonistas de GLP-1 e os seguintes temas: doenças biliares, gastroparesia e obstrução intestinal. Ao todo, 17 artigos foram consultados e abordados na discussão. Não estão descartados efeitos colaterais na via biliar, no estômago e no intestino. Ainda são necessários novos estudos que confirmem a relação causal entre os fatos, sendo as evidências atuais insuficientes para mitigar as dúvidas.
Downloads
Referências
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-85. Doi:10.1016/S2213-8587(19)30249-9
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30. Doi:10.1016/S0140-6736(19)31149-3.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. Doi:10.1056/NEJMoa1603827.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-44. Doi: 10.1056/NEJMoa160714.
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111-S124. Doi:10.2337/dc21-S009.
Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17(1):35-42. Doi:10.1089/dia.2014.0188.
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-6. Doi:10.1053/j.gastro.2011.02.018.
Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab. 2017;19(9):1233-41. Doi: 10.1111/dom.12926.
Pizzimenti V, Giandalia A, Cucinotta D, Russo GT, Smits M, Cutroneo PM, et al. Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. J Clin Pharm Ther. 2016;41(2):116-8. Doi: 10.1111/jcpt.12373.
Woronow D, Chamberlain C, Niak A, Avigan M, Houstoun M, Kortepeter C. Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration. JAMA Intern Med. 2022;182(10):1104-6. Doi: 10.1001/jamainternmed.2022.3810.
Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Intern Med. 2016;176(10):1474-81. Doi: 10.1001/jamainternmed.2016.1531.
Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018;363:k4880. Doi: 10.1136/bmj.k4880.
Dong YH, Wu JH, Chang CH, Lin JW, Wu LC, Toh S. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study. Pharmacotherapy. 2022;42(6):483-94. Doi: 10.1002/phar.2688.
Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019;42(10):1912-20. Doi: 10.2337/dc19-0415.
He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-9. Doi: 10.1001/jamainternmed.2022.0338.
Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;161:108087. Doi: 10.1016/j.diabres.2020.108087.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-7. Doi: 10.1001/jama.2023.19574.
Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson AM, Franzén S, et al. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia. 2021;64(10):2204-14. Doi: 10.1007/s00125-021-05508-1.
Kobori T, Onishi Y, Yoshida Y, Tahara T, Kikuchi T, Kubota T, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy. J Diabetes Investig. 2023;14(6):767-73. Doi: 10.1111/jdi.14005.
Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091. Doi: 10.1016/j.jclinane.2023.111091.
Stark JE, Cole JL, Ghazarian RN, Klass MJ. Impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) on Food Content During Esophagogastroduodenoscopy (EGD). Ann Pharmacother. 2022;56(8):922-6. Doi: 10.1177/10600280211055804.
Gudin B, Ladhari C, Robin P, Laroche ML, Babai S, Hillaire-Buys D, et al. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study. Therapie. 2020;75(6):641-7. Doi: 10.1016/j.therap.2020.02.024.
Faillie JL, Yin H, Yu OHY, Herrero A, Altwegg R, Renoux C, et al. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. Clin Pharmacol Ther. 2022;111(1):272-82. Doi: 10.1002/cpt.2430.
Ueda P, Wintzell V, Melbye M, Eliasson B, Söderling J, Gudbjörnsdottir S, et al. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study. Clin Gastroenterol Hepatol. 2024;22(6):1226-37.e14. Doi: 10.1016/j.cgh.2023.08.034.
Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007;133(1):244-55. Doi: 10.1053/j.gastro.2007.04.007
Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut. 2009;58(7):990-7. Doi: 10.1136/gut.2008.150870.
Rehfeld JF, Knop FK, Asmar A, Madsbad S, Holst JJ, Asmar M. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol. 2018;53(12):1429-32. Doi: 10.1080/00365521.2018.1530297.
Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab. 2016;18(12):1217-25. Doi: 10.1111/dom.12748.
Nexøe-Larsen CC, Sørensen PH, Hausner H, Agersnap M, Baekdal M, Brønden A, et al. Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes Obes Metab. 2018;20(11):2557-64. Doi: 10.1111/dom.13420.
Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91(5):1916-23. Doi: 10.1210/jc.2005-2220.
Kobori T, Onishi Y, Yoshida Y, Tahara T, Kikuchi T, Kubota T, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy. J Diabetes Investig. 2023;14(6):767-73. Doi: 10.1111/jdi.14005.
Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-5. Doi: 10.2337/db10-0474.
Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63(2):785-90. Doi: 10.2337/db13-0893.
Kalas MA, Galura GM, McCallum RW. Medication-Induced Gastroparesis: A Case Report. J Investig Med High Impact Case Rep. 2021;9:23247096211051919. Doi: 10.1177/23247096211051919.
Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023;70(8):1394-6. Doi:10.1007/s12630-023-02440-3.
Avraham SA, Hossein J, Somri F, Hawash N, Hochman O. Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss. Anaesth Rep. 2024;12(1):e12278. Doi: 10.1002/anr3.12278.
Queiroz VNF, Falsarella PM, Chaves RCF, Takaoka F, Socolowski LR, Garcia RG. Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence. Einstein (Sao Paulo). 2023;21:eRC0628. Doi: 10.31744/einstein_journal/2023RC0628.
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-62. Doi: 10.1111/dom.14280.
Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, Baekdal TA. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1594-603. Doi: 10.1111/dom.14373.
Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-9. Doi: 10.1111/dom.13120.
American Society of Anesthesiologists. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists [Internet]. 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017;43(5):430-7. Doi: 10.1016/j.diabet.2017.05.009.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Athina Maia, Luiz Felipe Nunes Palhares, Vinícius Silva Costa
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
